[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR080933A1 - Tratamiento de esclerosis multiple con masitinib - Google Patents

Tratamiento de esclerosis multiple con masitinib

Info

Publication number
AR080933A1
AR080933A1 ARP110101363A ARP110101363A AR080933A1 AR 080933 A1 AR080933 A1 AR 080933A1 AR P110101363 A ARP110101363 A AR P110101363A AR P110101363 A ARP110101363 A AR P110101363A AR 080933 A1 AR080933 A1 AR 080933A1
Authority
AR
Argentina
Prior art keywords
masitinib
treatment
multiple sclerosis
inhibitor
pharmaceutically acceptable
Prior art date
Application number
ARP110101363A
Other languages
English (en)
Inventor
Alain Moussy
Jean Pierre Kinet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of AR080933A1 publication Critical patent/AR080933A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inhibidor de la tirosina quinasa o un inhibidor de mastocitos, y en particular, masitinib o una sal farmacéuticamente aceptable de éste, para el tratamiento de la esclerosis multiple humana.
ARP110101363A 2010-04-20 2011-04-20 Tratamiento de esclerosis multiple con masitinib AR080933A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32594710P 2010-04-20 2010-04-20

Publications (1)

Publication Number Publication Date
AR080933A1 true AR080933A1 (es) 2012-05-16

Family

ID=44148452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101363A AR080933A1 (es) 2010-04-20 2011-04-20 Tratamiento de esclerosis multiple con masitinib

Country Status (4)

Country Link
US (1) US8906357B2 (es)
AR (1) AR080933A1 (es)
TW (1) TW201204360A (es)
WO (1) WO2011131705A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028299A1 (en) * 2012-08-13 2014-02-20 Biogen Idec Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
ES2899929T3 (es) 2016-03-25 2022-03-15 Ab Science Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica
AU2021223710A1 (en) * 2020-02-20 2022-07-28 Ab Science Masitinib for the treatment of a multiple sclerosis patient subpopulation
CN113456638A (zh) * 2021-08-06 2021-10-01 天津医科大学 盐酸安罗替尼在制备治疗多发性硬化药物中的用途
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316810T2 (de) 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
DK1791830T3 (da) * 2004-09-17 2011-04-18 Vertex Pharma Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
US7947262B2 (en) 2006-09-26 2011-05-24 Virginia Commonwealth University Use of fullerenes for the treatment of mast cell and basophil-mediated disease
NZ578944A (en) 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS

Also Published As

Publication number Publication date
US20130202555A1 (en) 2013-08-08
WO2011131705A1 (en) 2011-10-27
TW201204360A (en) 2012-02-01
US8906357B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
EA201201508A1 (ru) Комбинированная терапия
CL2014000297A1 (es) Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos .
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX367795B (es) Inhibidores de cdk.
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
CL2012003385A1 (es) Tratamiento para la incontinencia.
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
MX362442B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
CL2013003143A1 (es) Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
WO2014153495A9 (en) Novel stat3 inhibitors
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан

Legal Events

Date Code Title Description
FB Suspension of granting procedure